A new test to measure a specific protein modification linked to aging and disease.
Official title: An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts
Funded at Revel Pharmaceuticals INC. · NIH-10914230 · Data updated 2026-11-12
This study is working on a quick and affordable test to measure a marker linked to aging and certain diseases, making it easier for doctors to keep track of conditions related to sugar levels in the body, just like the diabetes test many people know.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Revel Pharmaceuticals INC. NIH-funded |
| Lab location | 1 site (San Francisco, UNITED STATES) |
| Project start | July 1, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $346,755 |
| NIH project number | 1R43GM154502-01 |
| Project ID | NIH-10914230 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing aging-related conditions or diseases associated with glycation and oxidative stress.
✕Less likely to help
Patients who do not have aging-related conditions or diseases linked to glycation may not benefit from this research.
What this research studies
This research focuses on developing a fast and cost-effective enzyme-based assay to measure Nε-carboxyethyl-lysine (CEL), a marker associated with aging and various diseases. The current methods for detecting CEL are slow and expensive, making them inaccessible for routine clinical use. By utilizing a newly discovered enzyme that oxidizes CEL, the researchers aim to create a simple test that can be performed quickly and at a lower cost, similar to the HbA1c test for diabetes. This advancement could facilitate better monitoring of glycation-related conditions and improve patient care.
Why it matters
Potential benefit: If successful, this research could provide a more accessible and affordable way to monitor aging and disease-related protein modifications, leading to better patient outcomes.
How similar studies have gone: Similar approaches have shown promise in other areas of biomarker detection, indicating potential for success in this novel application.
Where this research is happening
-
Revel Pharmaceuticals INC.
San Francisco, United States Active
Researchers
- Principal investigator: Cravens, Aaron — Revel Pharmaceuticals INC.
- Study coordinator: Cravens, Aaron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.